https://doi.org/10.55788/d3917b67
Antibody-mediated rejection is a leading cause of allograft rejection and is associated with poor long-term outcomes in patients receiving kidney transplantation [1]. The current double-blind, parallel-group, pilot trial (NCT05021484) randomised participants following kidney allografts 1:1 to 24 weeks of felzartamab or placebo. All participants underwent a biopsy at the end of treatment (24 weeks) and another at 52 weeks. Inclusion criteria were donor-specific positive active or chronic active antibody-mediated rejection, eGFR >20 mL/min/1.73 m2, and timing of the transplantation at least 6 months before study inclusion. The primary outcome was safety and tolerability, and the secondary outcomes covered the evolution of antibody-mediated rejection. Dr Katharina A. Mayer (Medical University of Vienna, Austria) presented the results [2].
With 11 participants included per treatment group, 1 placebo participant developed graft loss at week 14 due to antibody-mediated rejection. Treatment-emergent adverse events were more common with felzartamab (90.9% vs 63.6%), which could be traced back to infusion-related reactions (72.7% vs 0%). “However, the infusion-related reactions were mild-to-moderate in severity, were limited to the first dose of felzartamab and were generally easy to treat. We did not have any treatment-related discontinuations due to infusion-related reactions or any other adverse event”, highlighted Dr Mayer. The week 24 biopsy showed resolution of antibody-mediated rejection in 81.8% of participants with felzartamab versus 20.0% of participants with placebo (61.8% difference; 95% CI 18.6–100; RR 0.23; 95% CI 0.06–0.83). Of the 9 felzartamab participants showing a resolution, 33% had a recurrence of antibody-mediated rejection at the week 52 biopsy.
“We demonstrate that felzartamab had an overall acceptable safety profile when given on top of baseline immunosuppression to kidney transplant recipients”, summarised Dr Mayer. “Our preliminary efficacy data was promising and will be followed up in future trials.”
- Irish W, et al. Transplantation. 2021;105(3):648–659.
- Mayer KA. Randomized Phase 2 trial of felzartamab in humoral transplant rejection. Abstract #80, ERA 2024, 23–26 May, Stockholm, Sweden.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Clazakizumab improves albumin and inflammation in participants undergoing haemodialysis Next Article
APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy »
« Clazakizumab improves albumin and inflammation in participants undergoing haemodialysis Next Article
APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy »
Table of Contents: ERA 2024
Featured articles
Meet the Experts: Navigating Kidneys and Genes
Chronic Kidney Disease
FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease
Early phase data show albuminuria improvement with avenciguat
Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes
The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials
Kidney Transplantation and Dialysis
CD38 inhibition by felzartamab promising for resolution of antibody-mediated rejection following kidney allografts
TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen
KIR-HLA class I mismatch could be involved in antibody-mediated rejection of transplanted kidneys
IgA Nephropathy
Atrasentan shows positive interim results in IgA nephropathy: ALIGN phase 3 trial
Zigakibart slows down eGFR decline in IgA nephropathy
Long-term atacicept shows continued benefit in IgA nephropathy
APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy
Cardio-Renal Interplay
Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes
Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results
MERCURI-1: Perioperative empagliflozin shows renal protection following cardiac surgery
Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes
Other Nephrology
Preview of the new KDIGO Guidelines for ADPKD, available later in 2024
APPEAR-C3G: Iptacopan shows promise for complement 3 glomerulopathy
Anti-nephrin autoantibody positivity describes a unique subclass of podocytopathies
Active vitamin D plus low-dose prednisolone is an alternative to high-dose prednisolone in minimal change disease
Claudin-1 is a potential antibody target for crescent glomerulonephritis
Rituximab protocol based on PLA2R1 epitope spreading outperforms the standard GEMRITUX protocol in membranous nephropathy
The REACT score predicts relapse in ANCA-associated vasculitis
Related Articles
October 20, 2023
Analysing the Link Between Psoriasis and Chronic Kidney Disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com